Now, with the FDA already removing Ozempic, Mounjaro, and Wegovy from its shortage list, the compounded versions of GLP-1 drugs will no longer be a viable option
These results represent the greatest mean body-weight reduction reported to date for any incretin-based investigational therapy in a clinical trial of this duration.6 Although the triple-agonist mechanism offers substantial promise, glucagon receptor activation introduces theoretical safety concerns, including transient hyperglycemia, increased heart rate and potential hepatic effects
#SleepMedicine #Endocrinology #Cardiology #GLP1 #CPAP #Obesity #MetabolicHealth #NetworkMetaAnalysis #EvidenceBasedMedicine To view or add a comment, sign in More Relevant Posts SLEEP AND CARDIOVASCULAR HEALTH Continuing Medical Education (CME) Program Sleep disorders, particularly Obstructive Sleep Apnea (OSA), have been increasingly recognized as closely associated with many cardiovascular diseases such as hypertension, arrhythmias, heart failure, and stroke
Miracco C, Margherita De Santi M, Schurfeld K, Santopietro R, Lalinga AV, Fimiani M et al
Final Thoughts on MTHFR You may choose to do genetic testing for MTHFR defects, and if so, there are several labs available for this
